Equities researchers at Wedbush initiated coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research note issued on Thursday, Briefing.com reports. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 131.09% from the company’s previous close. […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 2,360,000 shares, a decrease of 20.5% from the November 30th total of 2,970,000 shares. Currently, 7.5% of the company’s stock are sold short. Based on […]
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Freeline Therapeutics (NASDAQ:FRLN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Analyst Ratings This is a breakdown […]
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Freeline Therapeutics (NASDAQ:FRLN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership. Analyst Recommendations This is a summary […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 3,730,000 shares, a decrease of 6.8% from the September 30th total of 4,000,000 shares. Approximately 12.1% of the company’s shares are short […]